
A single infusion of a CRISPR gene-editing therapy lowered LDL cholesterol and triglycerides by about half.
The effect held for 12 months with no serious side effects related to the treatment.
A related study showed even larger triglyceride reductions in patients with a severe form of the condition.
A one-time infusion of an experimental CRISPR-Cas9 therapy cut dangerous cholesterol by more than half in a Phase 1 human trial, and the benefit lasted a full year, the Cleveland Clinic reported.
Lead Author on Durability: "The durability of the lipid-lowering effect was impressive." — Dr. Luke Laffin, Cleveland Clinic cardiologist and first author of the study.
Lead Author on Safety: "It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment." — Dr. Luke Laffin.
Focus Area: The lasting cholesterol-lowering effect of the one-time CRISPR therapy CTX310 and its safety.
The trial enrolled 15 patients whose disorder had previously resisted medication. At the highest dose, LDL cholesterol fell 52.5% from baseline and triglycerides fell 47.8% after 12 months.
The therapy, CTX310, was given as a single infusion at doses from 0.1 to 0.8 mg/kg after pre-treatment with corticosteroids and antihistamines.
It delivers the CRISPR editing mechanism to the liver, where it switches off a gene called ANGPTL3, which is linked to both LDL cholesterol and triglyceride levels.
The results, published in the New England Journal of Medicine in August, extend findings reported after two months.
The study was funded by CRISPR Therapeutics AG of Switzerland.
Participants will undergo additional safety follow-up for 15 years, as recommended by the FDA for all gene-editing therapies, and researchers plan to test the treatment in a larger group of patients.
A related study presented last week at the American Heart Association's annual meeting in Chicago found CTX310 reduced triglycerides by 63% to 85% within 30 days of a single injection in 10 adults with severe hypertriglyceridemia.
CRISPR-Cas9 is a gene-editing technology that can modify or correct specific regions of a person's DNA to treat serious diseases.
High LDL cholesterol and triglycerides are both linked to heart disease, and the Phase 1 results are early evidence that must be confirmed in larger trials.
Follow Channel8 for continuous updates:
AI-Powered Eye Scans to Spot Early Signs of Heart Disease and Diabetes
New Immune Therapy Eliminates Deadly Childhood Brain Cancer in Mice, Human Trials Planned for 2027

